Genscript Biotech Corporation

Equities

1548

KYG3825B1059

Biotechnology & Medical Research

Market Closed - Hong Kong S.E. 09:08:27 12/07/2024 BST 5-day change 1st Jan Change
10 HKD +4.38% Intraday chart for Genscript Biotech Corporation +12.99% -49.65%
LockThis article is reserved for members
To unlock the article, REGISTER!
Already a customer? Log In
Genscript Biotech to Use 68,054 RSA Shares for Scheme, Over 425 Million Shares Available Under General Mandate MT
Genscript Biotech Grants Restricted Shares Under Incentive Scheme MT
Genscript Biotech Corporation Announces Board and Committee Changes CI
Genscript Biotech's Phase 3 Multiple Myeloma Drug Trial Yields Positive Results MT
Genscript Biotech Units Receive Milestone Payment of $30 Million MT
Genscript Biotech Corporation Announces Board Resignations and Changes in Composition of Board Committees CI
GenScript Biotech Corporation Launches FLASH Gene Service: The Most Affordable Gene Synthesis Solution on the Market CI
Genscript Biotech CEOs to Receive Shares Under Restricted Share Scheme MT
Hong Kong Stocks Rebound Following More than Expected Growth in China’s Manufacturing Sector MT
GenScript Biotech Draws Attention from US Congress Members; Shares Tank 18% MT
GenScript Biotech Shares Drop After U.S. Lawmakers Scrutinize Chinese Ties DJ
US lawmakers ask FBI for briefing on GenScript Biotech's links to China RE
US lawmakers ask FBI for briefing on GenScript Biotech's links to China RE
Legend Expects to Log Profit in 2026 MT
Legend Biotech's Loss Narrows in Q1 as Revenue Surges MT
GenScript Biotech Corporation Announces Self-Amplifying RNA Synthesis Service for Advanced Therapeutic Applications CI
Multiply Labs and GenScript Biotech Corporation Collaborate to Automate Cell Isolation and Enrichment Phase of Cell Therapy Manufacturing CI
Genscript Biotech Unit Gets Approval for Blood Cancer Drug by European Commission MT
Genscript Biotech's Unit Logs $157 Million in Q1 Sales of Blood Cancer Drug MT
Genscript Biotech Corporation Announces Directorate Appointments and Change in Composition of Board Committee CI
Genscript Biotech Unit's Refractory Multiple Myeloma Drug Gets FDA Approval MT
Genscript Biotech's US Unit Secures FDA Nod for Anti-Cancer Medication MT
Genscript Biotech Issues 444,598 Shares to Three Grantees Under Restricted Share Scheme MT
Genscript Biotech's 2023 Loss Widens; Misses Revenue Estimates MT
Transcript : Genscript Biotech Corporation, 2023 Earnings Call, Mar 11, 2024
Chart Genscript Biotech Corporation
More charts
Genscript Biotech Corporation is a Hong Kong-based investment holding company principally engaged in life science research and related businesses. The Company operates through four segments. Life Sciences Research Services segment includes gene and peptide synthesis, deoxyribonucleic acid (DNA) and primer synthesis, DNA sequencing, customized antibody production, protein expression and the production of stable cell lines. Preclinical Drug Development Services segment includes protein and antibody engineering, the study of in vitro drug and the study of in vivo drug. Life Sciences Research Catalog Products segment provides antibodies, recombinant proteins, equipment for protein isolation and analysis, molecular biology reagents, peptide, biochemicals and stable cell lines. Industrial Synthetic Biology Products segment is engaged in the development and production of industrial enzymes.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
1.281 USD
Average target price
3.091 USD
Spread / Average Target
+141.29%
Consensus
  1. Stock Market
  2. Equities
  3. 1548 Stock
  4. News Genscript Biotech Corporation
  5. Genscript Biotech Unit Gets Approval for Blood Cancer Drug by European Commission